# US 2017/0281566 A1 · Combinations of lsd1 inhibitors for the treatment of hematological malignancies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281566 A1
- Document ID: US20170281566A1
- Status: Published application
- Kind: A1
- Application number: 15/458,636
- Filed: 2017-06-23
- Published: 2017-10-05
- Earliest claimed: 2016-03-15
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Filippo CICERI; Serena LUNARDI; Tamara MAES; Cristina MASCARÓ CRUSAT; Iñigo TIRAPU FERNÁNDEZ DE LA CUESTA
- Web page: https://patentgrep.com/patent/US20170281566A1

## CPC

- A61K 31/015: carbocyclic
- A61K 31/12: Ketones
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/17: having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine (isoureas, isothioureas A61K31/155; sulfonylureas A61K31/64)
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/203: Retinoic acids {; Salts thereof}
- A61K 31/282: Platinum compounds
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375)
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 31/64: Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 33/36: Arsenic; Compounds thereof
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The instant invention relates to combinations of the compound of formula (I) or pharmaceutically acceptable salts thereof with other active pharmaceutical ingredients pharmaceutical compositions comprising them, and their use as medicaments, particularly for the treatment of hematological malignancies.

## Claims

### Claim 1

A combination comprising a compound of formula (I):
or a pharmaceutically acceptable salt thereof, and one or more therapeutic agents selected from a retinoic acid analogue, a nucleoside analogue, a DOT1L inhibitor, a HDAC inhibitor, a demethylating agent, an FLT3 inhibitor, a BCL2 inhibitor, an MDM2 inhibitor, a c-KIT inhibitor, a BET inhibitor, an anthracycline, arsenic trioxide, hydroxyurea and pharmaceutically acceptable salts thereof.

### Claim 2 (depends on 1)

The combination according to claim 1 comprising a compound of formula (I):
or a pharmaceutically acceptable salt thereof, and one or more therapeutic agents selected from tretinoin, cytarabine, sapacitabine, clofarabine, elacytarabine, fludarabine, cytarabine ocfosfate, gemcitabine, 2-chloro-2-deoxyadenosine (also known as 2-CDA), troxacitabine, forodesine, nelarabine, pinometostat, EPZ-004777, SGC-0946, Belinostat, Panobinostat, Vorinostat, Ricolinostat, Entinostat, Mocetinostat, Abexinostat, Resminostat, Givinostat, Quisinostat, decitabine, azacitidine, guadecitabine, Quizartinib, Sorafenib, Sunitinib, Lestaurtinib, ABT-737, Navitoclax, Venetoclax, Obatoclax, Nutlin-3A, dasatinib, imatinib, JQ1, GSK1210151A, MS 436, GSK525762, OTX-015, CPI-203, GSK1324726A, daunorubicin, doxorubicin, idarubicin, arsenic trioxide, hydroxyurea, and pharmaceutically acceptable salts thereof.

### Claim 3 (depends on 1)

The combination according to claim 1 comprising a compound of formula (I):
or a pharmaceutically acceptable salt thereof, and one or more therapeutic agents selected from tretinoin, cytarabine, pinometostat, EPZ-00477, Vorinostat, Ricolinostat, Entinostat, decitabine, azacitidine, Quizartinib, ABT-737, Nutlin-3A, dasatinib, JQ1, daunorubicin, arsenic trioxide, hydroxyurea, and pharmaceutically acceptable salts thereof.

### Claim 4 (depends on 1)

The combination according to claim 1 comprising a compound of formula (I):
or a pharmaceutically acceptable salt thereof, and a retinoic acid analogue or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 4)

The combination according to claim 4, wherein the retinoic acid analogue is tretinoin or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The combination according to claim 1 comprising a compound of formula (I):
or a pharmaceutically acceptable salt thereof, and a nucleoside analogue or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 6)

The combination according to claim 6, wherein the nucleoside analogue is cytarabine or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

The combination according to claim 1 comprising a compound of formula (I):
or a pharmaceutically acceptable salt thereof, and a DOT1L inhibitor or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 8)

The combination according to claim 8, wherein the DOT1L inhibitor is pinometostat, EPZ-004777 or SGC-0946, or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1)

The combination according to claim 1 comprising a compound of formula (I):
or a pharmaceutically acceptable salt thereof, and an HDAC inhibitor or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 10)

The combination according to claim 10, wherein the HDAC inhibitor is Belinostat, Panobinostat, Vorinostat, Ricolinostat, Entinostat, Mocetinostat, Abexinostat, Resminostat, Givinostat, Quisinostat, or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 1)

The combination according to claim 1 comprising a compound of formula (I):
or a pharmaceutically acceptable salt thereof, and a demethylating agent or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 12)

The combination according to claim 12, wherein the demethylating agent is decitabine or azacitidine, or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

The combination according to claim 1 comprising a compound of formula (I):
or a pharmaceutically acceptable salt thereof, and an FLT3 inhibitor or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 14)

The combination according to claim 14, wherein the FLT3 inhibitor is Quizartinib, Sorafenib, Sunitinib and Lestaurtinib, or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 1)

The combination according to claim 1 comprising a compound of formula (I):
or a pharmaceutically acceptable salt thereof, and a BCL2 inhibitor or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 16)

The combination according to claim 16, wherein the BCL2 inhibitor is ABT-737, Navitoclax, Venetoclax, Obatoclax, or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 1)

The combination according to claim 1 comprising a compound of formula (I):
or a pharmaceutically acceptable salt thereof, and a MDM2 inhibitor or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 18)

The combination according to claim 18, wherein the MDM2 inhibitor is Nutlin-3A, or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 1)

The combination according to claim 1 comprising a compound of formula (I):
or a pharmaceutically acceptable salt thereof, and a c-KIT inhibitor or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 20)

The combination according to claim 20, wherein the c-KIT inhibitor is dasatinib or imatinib, or a pharmaceutically acceptable salt thereof.

### Claim 22 (depends on 1)

The combination according to claim 1 comprising a compound of formula (I):
or a pharmaceutically acceptable salt thereof, and a BET inhibitor or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 22)

The combination according to claim 22, wherein the BET inhibitor is JQ1, GSK1210151A, MS 436, GSK525762, OTX-015, CPI-203, GSK1324726A, or a pharmaceutically acceptable salt thereof.

### Claim 24 (depends on 1)

The combination according to claim 1, comprising a compound of formula (I):
or a pharmaceutically acceptable salt thereof, and an anthracycline or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 24)

The combination according to claim 24, wherein the anthracycline is daunorubicin, idarubicin, or a pharmaceutically acceptable salt thereof.

### Claim 26 (depends on 25)

The combination according to claim 25, which further comprises cytarabine, or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 1)

The combination according to claim 1 comprising a compound of formula (I):
or a pharmaceutically acceptable salt thereof, and arsenic trioxide.

### Claim 28 (depends on 1)

The combination according to claim 1 comprising a compound of formula (I):
or a pharmaceutically acceptable salt thereof, and hydroxyurea.

### Claim 29 (depends on 1)

A pharmaceutical composition comprising a combination according to claim 1 and one or more pharmaceutically acceptable excipients.

### Claim at position 30

30-32. (canceled)

### Claim 33 (depends on 1)

A method for the treatment of a hematological malignancy in a patient in need thereof, which method comprises administering a therapeutically effective amount of a combination according to claim 1 to said patient.

### Claim 34 (depends on 29)

A method for the treatment of a hematological malignancy in a patient in need thereof, which method comprises administering the pharmaceutical composition according to claim 29 to said patient.

### Claim at position 33

35-36. (canceled)

### Claim 37 (depends on 33, 34)

The method of claim 33 or 34, wherein the hematological malignancy is a myeloid hematological malignancy.

### Claim 38 (depends on 37)

The method of claim 37, wherein the myeloid hematological malignancy is acute myeloid leukemia.

### Claim 39 (depends on 37)

The method of claim 37, wherein the myeloid hematological malignancy is chronic myelogenus leukemia.

### Claim 40 (depends on 37)

The method of claim 37, wherein the myeloid hematological malignancy is myelodysplastic syndrome.

### Claim 41 (depends on 37)

The method of claim 37, wherein the myeloid hematological malignancy is a myeloproliferative disease.

### Claim 42 (depends on 41)

The method of claim 41, wherein the myeloproliferative disease is selected from the group consisting of myelofibrosis, acute biphenotypic leukemia, Polycythemia vera, Chronic eosinophilic leukemia/Hypereosinophilic syndrome, Essential thrombocytosis, and Chronic eosinophilic leukemia/Hypereosinophilic syndrome.

### Claim 43 (depends on 37)

The method of claim 37, wherein the myeloid hematological malignancy is a myeloid hematological malignancy with translocation or rearrangements involving MLL, AF9, AF4, AF10, AML1, ETO, CALM; or mutation in NPM1 or Notch1, or LSD1 overexpression.

### Claim 44 (depends on 33, 34)

The method of claim 33 or 34, wherein the hematological malignancy is a lymphoid hematological malignancy.

### Claim 45 (depends on 44)

The method of claim 44, wherein the lymphoid hematological malignancy is acute lymphoblastic leukemia.

### Claim 46 (depends on 44)

The method of claim 44, wherein the lymphoid hematological malignancy is a lymphoid hematological malignancy with translocation or rearrangements involving MLL, AF9, AF4, AF10, AML1, ETO, CALM; or mutation in NPM1 or Notch1, or LSD1 overexpression.

### Claim 47 (depends on 33)

The method of claim 33, wherein the patient is a human being.

### Claim 48

(canceled)
